These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 25723369)
41. Forum discusses biosimilars, better biologicals. Thompson CA Am J Health Syst Pharm; 2011 Dec; 68(23):2210. PubMed ID: 22095804 [No Abstract] [Full Text] [Related]
42. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim. Grewal S; Ramsey S; Balu S; Carlson JJ Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):447-454. PubMed ID: 29757040 [TBL] [Abstract][Full Text] [Related]
43. Fate of cost-saving biosimilar drugs may hinge on naming policy. Johnson SR Mod Healthc; 2016 Aug; 45(27):7, 9. PubMed ID: 30387953 [No Abstract] [Full Text] [Related]
44. Biosimilars and the European experience: implications for the United States. Megerlin F; Lopert R; Taymor K; Trouvin JH Health Aff (Millwood); 2013 Oct; 32(10):1803-10. PubMed ID: 24101072 [TBL] [Abstract][Full Text] [Related]
45. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology]. Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629 [TBL] [Abstract][Full Text] [Related]
46. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars. Henry D; Taylor C Semin Oncol; 2014 Apr; 41 Suppl 3():S13-20. PubMed ID: 24767632 [TBL] [Abstract][Full Text] [Related]
47. Monoclonal antibody biosimilars. Udpa N; Million RP Nat Rev Drug Discov; 2016 Jan; 15(1):13-4. PubMed ID: 26678619 [No Abstract] [Full Text] [Related]
48. Biosimilars for Rheumatoid Arthritis: Don't Count Them Out Quite Yet. Rychlick N Manag Care; 2018 Jan; 27(1):29. PubMed ID: 29369768 [TBL] [Abstract][Full Text] [Related]
50. Biosimilars. Ross A; Richard K Conn Med; 2015 May; 79(5):295-9. PubMed ID: 26245019 [No Abstract] [Full Text] [Related]
51. Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018. Hernandez I; Good CB; Shrank WH; Gellad WF JAMA; 2019 Apr; 321(16):1627-1629. PubMed ID: 30907933 [TBL] [Abstract][Full Text] [Related]
52. Emerging Opportunities and Challenges of Biosimilars in Oncology Practice. Lyman GH J Oncol Pract; 2017 Sep; 13(9_suppl):7s-9s. PubMed ID: 28898591 [No Abstract] [Full Text] [Related]
53. Biosimilars: a cure to the U.S. health care cost conundrum? Hirsch BR; Lyman GH Blood Rev; 2014 Nov; 28(6):263-8. PubMed ID: 25260225 [TBL] [Abstract][Full Text] [Related]
54. Generics and Biosimilars: Barriers and Opportunities. Scheckel CJ; Rajkumar SV Mayo Clin Proc; 2021 Dec; 96(12):2947-2957. PubMed ID: 34728057 [No Abstract] [Full Text] [Related]
55. Biosimilar insulin could offer patients cost-saving options. Karlovitch S Am J Manag Care; 2019 Sep; 25(10 Spec No.):. PubMed ID: 31860243 [No Abstract] [Full Text] [Related]
56. Biosimilars take center stage. Adams KT Manag Care; 2014 Apr; 23(4):44-6. PubMed ID: 24864533 [No Abstract] [Full Text] [Related]
57. A long war begins: biosimilars versus patented biologics. Bocquet F; Paubel P J Med Econ; 2015; 18(12):1071-3. PubMed ID: 26212478 [No Abstract] [Full Text] [Related]
58. Pfizer-Allergan deal could reduce biosimilar cost savings. Johnson SR Mod Healthc; 2015 Dec; 45(49):12. PubMed ID: 26875340 [No Abstract] [Full Text] [Related]